| Title |
Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma
|
|---|---|
| Published in |
Blood, December 2016
|
| DOI | 10.1182/blood-2016-08-685073 |
| Pubmed ID | |
| Authors |
Jonathon B Cohen, Madhusmita Behera, Carrie A Thompson, Christopher R Flowers |
| Abstract |
Up to 50% of patients with Hodgkin lymphoma and diffuse large b-cell lymphoma will relapse and require additional therapy. Although surveillance imaging is commonly performed in clinical practice, its ability to identify asymptomatic relapses and improve survival for patients is not well-defined. We evaluated the role of surveillance imaging in relapse detection and reviewed its impact on survival for relapsed patients, and found that current imaging approaches do not detect most relapses prior to clinical signs and symptoms or improve survival. |
X Demographics
The data shown below were collected from the profiles of 21 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 19% |
| Spain | 3 | 14% |
| Canada | 2 | 10% |
| Mexico | 1 | 5% |
| Unknown | 11 | 52% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 14 | 67% |
| Scientists | 3 | 14% |
| Practitioners (doctors, other healthcare professionals) | 2 | 10% |
| Science communicators (journalists, bloggers, editors) | 2 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 43 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 16% |
| Other | 6 | 14% |
| Professor | 5 | 12% |
| Student > Bachelor | 4 | 9% |
| Student > Postgraduate | 4 | 9% |
| Other | 9 | 21% |
| Unknown | 8 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 67% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Business, Management and Accounting | 1 | 2% |
| Immunology and Microbiology | 1 | 2% |
| Agricultural and Biological Sciences | 1 | 2% |
| Other | 2 | 5% |
| Unknown | 8 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 September 2019.
All research outputs
#2,966,823
of 25,377,790 outputs
Outputs from Blood
#3,619
of 33,240 outputs
Outputs of similar age
#55,009
of 419,629 outputs
Outputs of similar age from Blood
#118
of 791 outputs
Altmetric has tracked 25,377,790 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 33,240 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 419,629 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 791 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.